Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Nutt

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
American Journal of Medical Genetics|January 25, 2002
Age at onset of Parkinson disease and apolipoprotein E genotypesSepideh Zareparsi, Richard Camicioli, Gary Sexton, et al.
Parkinsonism & Related Disorders|September 7, 2015
Life-sustaining treatment orders, location of death and co-morbid conditions in decedents with Parkinson's diseaseKeiran K Tuck, Dana M Zive, Terri A Schmidt, et al.
Parkinsonism & Related Disorders|February 24, 2019
Overview of the cholinergic contribution to gait, balance and falls in Parkinson's diseaseRosie Morris, Douglas N Martini, Tara Madhyastha, et al.
Acta Neuropsychiatrica|May 21, 2019
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line ratOskar Jefsen, Kristoffer Højgaard, Sofie Laage Christiansen, et al.
Journal of Neurologic Physical Therapy : JNPT|August 27, 2015
Effects of Group, Individual, and Home Exercise in Persons With Parkinson Disease: A Randomized Clinical TrialLaurie A King, Jennifer Wilhelm, Yiyi Chen, et al.
International Review of Neurobiology|March 30, 2024
AUD in perspectiveAndrea de Bejczy, Giovanni Addolorato, Henri-Jean Aubin, et al.
JAMA|May 27, 2004
Measuring the effects of therapy in Parkinson diseaseClifford W Shults, Richard Haas, David Oakes, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Neuromodulation : Journal of the International Neuromodulation Society|September 13, 2013
Deep brain stimulation may improve quality of life in people with Parkinson's disease without affecting caregiver burdenGenko Oyama, Michael S Okun, Peter Schmidt, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
American Journal of Medical Genetics|January 25, 2002
Age at onset of Parkinson disease and apolipoprotein E genotypesSepideh Zareparsi, Richard Camicioli, Gary Sexton, et al.
Parkinsonism & Related Disorders|September 7, 2015
Life-sustaining treatment orders, location of death and co-morbid conditions in decedents with Parkinson's diseaseKeiran K Tuck, Dana M Zive, Terri A Schmidt, et al.
Parkinsonism & Related Disorders|February 24, 2019
Overview of the cholinergic contribution to gait, balance and falls in Parkinson's diseaseRosie Morris, Douglas N Martini, Tara Madhyastha, et al.
Acta Neuropsychiatrica|May 21, 2019
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line ratOskar Jefsen, Kristoffer Højgaard, Sofie Laage Christiansen, et al.
Journal of Neurologic Physical Therapy : JNPT|August 27, 2015
Effects of Group, Individual, and Home Exercise in Persons With Parkinson Disease: A Randomized Clinical TrialLaurie A King, Jennifer Wilhelm, Yiyi Chen, et al.
International Review of Neurobiology|March 30, 2024
AUD in perspectiveAndrea de Bejczy, Giovanni Addolorato, Henri-Jean Aubin, et al.
JAMA|May 27, 2004
Measuring the effects of therapy in Parkinson diseaseClifford W Shults, Richard Haas, David Oakes, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Neuromodulation : Journal of the International Neuromodulation Society|September 13, 2013
Deep brain stimulation may improve quality of life in people with Parkinson's disease without affecting caregiver burdenGenko Oyama, Michael S Okun, Peter Schmidt, et al.
Pageof 6